Headquartered in Pittsburgh, Pennsylvania, Axe Compute Inc., established in 2002 and formerly known as Predictive Oncology Inc. until its December 2025 renaming, is an enterprise that leverages profound scientific insights and artificial intelligence (AI) to advance the discovery and development of cancer treatments. The company's operations are divided into two distinct segments. Its Pittsburgh division offers AI-driven services, utilizing an exclusive biobank containing over 150,000 tumor samples, and engineers specialized 3D cell culture models vital for drug advancement. Meanwhile, the Eagan division produces the FDA-approved STREAMWAY System and related products, which facilitate automated medical fluid waste management and direct patient-to-drain fluid disposal. Additionally, Axe Compute maintains a strategic partnership with Every Cure to identify and prioritize existing pharmaceuticals for repurposing.
